<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Etidronate (United States: Not available): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Etidronate (United States: Not available): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Etidronate (United States: Not available): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="8426" href="/d/html/8426.html" rel="external">see "Etidronate (United States: Not available): Drug information"</a> and <a class="drug drug_patient" data-topicid="12456" href="/d/html/12456.html" rel="external">see "Etidronate (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866841"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Etidronate [DSC];</li>
<li>CO Etidronate [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1058536"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote, Hypercalcemia</span>;</li>
<li>
<span class="list-set-name">Bisphosphonate Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812510"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Etidronate 200 mg and 400 mg tablets have been discontinued in the US for more than 1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4025485-01f8-487b-9536-0d013cc9cafc">Heterotopic ossification, traumatic brain injury</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heterotopic ossification, traumatic brain injury:</b> Limited data available: Children and Adolescents: Oral: Initial: 20 mg/kg/dose once daily for 2 to 4 weeks, then decrease to 10 mg/kg/dose once daily for 12 weeks to 1 year (Hurvitz 1992).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729718"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Manufacturer's labeling recommends decreasing the dose when GFR is reduced in adults; however, no specific dosage adjustments are provided. Use with caution and monitor closely; etidronate is eliminated intact via the kidneys.</p></div>
<div class="block dohp drugH1Div" id="F52729719"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F168980"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8426" href="/d/html/8426.html" rel="external">see "Etidronate (United States: Not available): Drug information"</a>)</p>
<p style="text-indent:0em;margin-left:0em;display:inline">
<b>Note: </b>Etidronate 200 mg and 400 mg tablets have been discontinued in the United States for &gt;1 year.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e26968cd-a76e-40af-abcf-7737ae0dba16">Paget disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Paget disease:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial:</i> 5 mg/kg/day (not to exceed 6 months) is recommended as initial therapy; if higher doses are needed, may give 5 to 10 mg/kg/day (not to exceed 6 months) or 11 to 20 mg/kg/day (not to exceed 3 months). Doses &gt;10 mg/kg/day should be used only when lower doses are ineffective or there is a need to suppress rapid bone turnover (ie, potential for irreversible neurologic damage) or reduce elevated cardiac output. Doses &gt;20 mg/kg/day are <b>not</b> recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Re-treatment:</i> Initiate only after etidronate-free period ≥90 days. Monitor patients every 3 to 6 months. Re-treatment regimens are the same as for initial treatment. In cases where the original dose is not adequate, consider increasing the dose within the recommended guidelines.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="35e4ef4c-8ac5-4d40-bbb9-8ee943fd0050">Heterotopic ossification</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heterotopic ossification:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Caused by spinal cord injury:</i> 20 mg/kg/day for 2 weeks, then 10 mg/kg/day for 10 weeks; total treatment period: 12 weeks</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Complicating total hip replacement:</i> 20 mg/kg/day for 1 month preoperatively then 20 mg/kg/day for 3 months postoperatively; total treatment period is 4 months</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Re-treatment:</i> Has not been studied.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990058"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Manufacturer’s labeling recommends decreasing the dose when GFR is reduced; however, no specific dosage adjustments are provided. Use with caution and monitor closely; etidronate is eliminated intact via the kidneys.</p></div>
<div class="block doha drugH1Div" id="F50987306"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F168946"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gastrointestinal: Diarrhea (≤30%; dose dependent), nausea (≤30%; dose dependent)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Neuromuscular &amp; skeletal: Ostealgia (10% to 20%; dose dependent)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Postmarketing and/or case reports: Agranulocytosis, alopecia, amnesia, angioedema, arthralgia, arthritis, bone fracture, confusion, depression, erythema multiforme, esophagitis, exacerbation of asthma, exacerbation of peptic ulcer, folliculitis, gastritis, glossitis, glossopyrosis, hallucination, headache, hypersensitivity reaction, leg cramps, leukemia, leukopenia, maculopapular rash, osteomalacia, osteonecrosis of the jaw, pancytopenia, paresthesia, pruritus, skin rash (macular), Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria </p></div>
<div class="block coi drugH1Div" id="F168961"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to bisphosphonates or any component of the formulation; overt osteomalacia; patients with abnormalities of the esophagus (eg, stricture, achalasia) which delay esophageal emptying</p></div>
<div class="block war drugH1Div" id="F168943"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone/joint/muscle pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fracture risk: Do not exceed recommended dose or use continuously for &gt;6 months in patients with Paget's disease; risk of osteomalacia or fractures may be increased. Long bones with predominantly lytic lesions may be prone to fracture, particularly in patients unresponsive to treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI mucosa irritation: May cause irritation to upper GI mucosa. Esophagitis, dysphagia, esophageal ulcers, esophageal erosions, and esophageal stricture (rare) have been reported with oral bisphosphonates; risk increases in patients unable to comply with dosing instructions. Use with caution in patients with dysphagia, esophageal disease, gastritis, duodenitis, or ulcers (may worsen underlying condition). Discontinue use if new or worsening symptoms develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving bisphosphonates; this has been observed primarily following dental procedures such as tooth extractions and in cancer patients receiving IV bisphosphonates, but has also occurred in patients with postmenopausal osteoporosis and other diagnoses receiving oral bisphosphonates. Risk factors for MRONJ include invasive dental procedures (eg, tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant chemotherapy, radiotherapy, or corticosteroids; anemia, coagulopathy, infection, ill-fitting dentures, or preexisting dental disease. According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), MRONJ has been associated with bisphosphonate and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy. The manufacturer’s labeling states that discontinuing bisphosphonates in patients requiring invasive dental procedures may reduce the risk of ONJ and clinical judgment should guide the decision. However, the AAOMS suggests there is currently no evidence that interrupting oral bisphosphonate therapy alters the risk of ONJ following tooth extraction, and that in patients receiving oral bisphosphonates for &lt;4 years who have no clinical risk factors, no alternations or delay in any procedure common to oral/maxillofacial surgeons, periodontists, and other dental providers is necessary (special considerations apply to patients receiving dental implants). Conversely, in patients receiving oral bisphosphonates for &gt;4 years <b>or</b> in patients receiving oral bisphosphonates for &lt;4 years who have also taken corticosteroids or antiangiogenic medications concomitantly, the AAOMS recommends considering a 2-month drug free period prior to invasive dental procedures (recommendation based on a theoretical benefit). Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]). According to the manufacturer, discontinuation of the bisphosphonate therapy should be considered (based on risk/benefit evaluation) in patients who develop ONJ.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Altered absorption and ulceration risk: Avoid oral bisphosphates after bariatric surgery; inadequate oral absorption and potential anastomotic ulceration may occur. If therapy is indicated, IV administered bisphosphonates are recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Enterocolitis: Use with caution in patients with enterocolitis; diarrhea has been reported at high doses and therapy may need to be withheld.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone mineralization: May retard mineralization of bone; treatment may need delayed or interrupted until callus is present.</p>
<p style="text-indent:-2em;margin-left:4em;">• Calcium/vitamin D intake: Ensure adequate calcium and vitamin D intake.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878449"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Prolonged therapy may lead to rachitic syndrome; doses of ≥10 mg/kg/day for ~1 year have been associated with rachitic syndrome when etidronate was used to prevent heterotopic ossifications or soft tissue calcifications; radiologic changes and symptoms have been reversed upon discontinuation.</p></div>
<div class="block prod-avail drugH1Div" id="F55435137"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Etidronate 200 mg and 400 mg tablets have been discontinued in the US for more than 1 year.</p></div>
<div class="block geq drugH1Div" id="F168939"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F168963"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Etidronate Disodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $4.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $8.64</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866842"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as disodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg [DSC], 400 mg [DSC]</p></div>
<div class="block admp drugH1Div" id="F52612781"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer on an empty stomach with a full glass of plain water (6 to 8 oz), 2 hours before meals. Patients should be instructed to stay upright (not to lie down) after taking the medication. Dose should be taken once daily, however, if GI upset occurs, doses can be divided.</p></div>
<div class="block adm drugH1Div" id="F168958"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral: </b>Administer tablet on an empty stomach with a full glass of plain water (6 to 8 oz) 2 hours before food. Patients should be instructed to stay upright (not to lie down) after taking the medication. If gastrointestinal discomfort occurs, the dose may be divided.</p></div>
<div class="block sts drugH1Div" id="F168972"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at controlled room temperature of 25°C (77°F). </p></div>
<div class="block usep drugH1Div" id="F53566832"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Symptomatic treatment of Paget's disease of bone and prevention and treatment of heterotopic ossification following spinal cord injury or total hip replacement (FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F169020"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Etidronate may be confused with etomidate</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299302"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F168948"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives. Aminoglycosides may enhance the nephrotoxic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiogenesis Inhibitors (Systemic): May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May diminish the therapeutic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyvalent Cation Containing Products: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Medronate: Etidronate may diminish the diagnostic effect of Technetium Tc 99m Medronate.  Management: Consider performing bone scintigraphy with technetium Tc 99m medronate before, or at least 2 to 4 weeks after, etidronate administration.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F168974"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food and/or supplements decrease the absorption and bioavailability of the drug. Management: Administer tablet on an empty stomach with a full glass of plain water or fruit juice (6 to 8 oz) 2 hours before food. Avoid administering foods/supplements with calcium, iron, or magnesium within 2 hours of drug. Do not take with mineral water or other beverages.</p></div>
<div class="block dic drugH1Div" id="F168965"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Ensure adequate calcium and vitamin D intake; women and men &gt;50 years of age should consume 1,200 to 1,500 mg/day of elemental calcium and 800 to 1,000 units/day of vitamin D. Tablet should be taken with water or fruit juice on an empty stomach; avoid administering foods/supplements with calcium, iron, or magnesium within 2 hours of drug. Do not take with mineral water or with other beverages.</p></div>
<div class="block rep_considerations drugH1Div" id="F49305358"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Bisphosphonates are incorporated into the bone matrix and gradually released over time. Because exposure prior to pregnancy may theoretically increase the risk of fetal harm, use in premenopausal females should be reserved for special circumstances when rapid bone loss is occurring (Bhalla 2010; Pereira 2012; Stathopoulos 2011).</p></div>
<div class="block pri drugH1Div" id="F168964"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">It is not known if bisphosphonates cross the placenta, but based on their lower molecular weight, fetal exposure is expected (Djokanovic 2008; Stathopoulos 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Information related to the use of etidronate in pregnancy is available from case reports and small retrospective studies (Agarwal 2020; Levy 2009; Sokal 2019; Vujasinovic-Stupar 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Bisphosphonates are incorporated into the bone matrix and gradually released over time. The amount available in the systemic circulation varies by drug, dose, and duration of therapy. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy (hypocalcemia, low birth weight, and decreased gestation have been observed in some case reports); however, available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events (Djokanovic 2008; Green 2014; Levy 2009; Machairiotis 2019; Sokal 2019; Stathopoulos 2011). Exposed infants should be monitored for hypocalcemia after birth (Djokanovic 2008; Stathopoulos 2011).</p></div>
<div class="block mopp drugH1Div" id="F53566824"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum calcium, phosphate, creatinine, BUN, alkaline phosphatase, 25(OH)D, pain </p></div>
<div class="block pha drugH1Div" id="F168942"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Decreases bone resorption by inhibiting osteocytic osteolysis; decreases mineral release and matrix or collagen breakdown in bone</p></div>
<div class="block phk drugH1Div" id="F168960"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 1 to 3 months</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Can persist for 12 months without continuous therapy</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: ~3%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: None</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 1 to 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily urine (50% as unchanged drug); feces (as unabsorbed drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038614"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Difosfen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Didronel</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Didronel</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Didronel | Osteodidronel</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Didronel</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Osteotop</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bang de lin | Etidronate disod. | Gen de | Yilin | Zhong bao bi xin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Difosfen</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Pleostat</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Didronate | Didronel | Diphos | Etidron hexal | Etidronat</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Difosfen | Osteol</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Etidrone | Ossidron</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Difosfen | Osteum</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Didronate</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Didronel | Etidronate de Sodium G Gam | Etidronate de Sodium Merck</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Didronel | Didronel brocades | Etidronate</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Osteoton</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Didronel</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Didronel</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Didronel</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Etifem</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Didronel</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Didronel</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Adbon | Dinol | Osteum</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Pleostat</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Didronel</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Didronel</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Difosfen</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Didronel</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Didronate</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Arrow-Etidronate | Didronel | Etidrate</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Osteotop</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Etinat</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Didronel | Difosfen | Ostedron</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Didronel</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Didronel</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Didronate | Etidrel</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Difosfen</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Pleostat</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Pleostat</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Difosfen</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Didronel</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Didronat</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Etibon</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Difosfen</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Didronel</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32490054">
<a name="32490054"></a>Agarwal N, Agarwal U, Alfirevic Z, et al. Skeletal abnormalities secondary to antenatal etidronate treatment for suspected generalised arterial calcification of infancy. <i>Bone Rep</i>. 2020;12:100280. doi:10.1016/j.bonr.2020.100280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/32490054/pubmed" id="32490054" target="_blank">32490054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16873332">
<a name="16873332"></a>American Dental Association Council on Scientific Affairs. Dental Management of Patients Receiving Oral Bisphosphonate Therapy. <i>JADA.</i> 2006;137(8):1144-1150. http://jada.ada.org/article/S0002-8177(14)64960-6/pdf
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/16873332/pubmed" id="16873332" target="_blank">16873332</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Author Unknown. Safety Update: Bone-Building Drugs: Risks Explained. <i>Consum Rep Health.</i> 2006;18(5):3.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20534366">
<a name="20534366"></a>Bhalla AK. Management of Osteoporosis in a Pre-menopausal Woman. <i>Best Pract Res Clin Rheumatol.</i> 2010;24(3):313-327.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/20534366/pubmed" id="20534366" target="_blank">20534366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19175968">
<a name="19175968"></a>Djokanovic N, Klieger-Grossmann C, and Koren G. Does Treatment With Bisphosphonates Endanger the Human Pregnancy? <i>J Obstet Gynaecol Can.</i> 2008;30(12):1146-1148.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/19175968/pubmed" id="19175968" target="_blank">19175968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19047674">
<a name="19047674"></a>Edwards BJ, Hellstein JW, Jacobsen PL, et al. Updated Recommendations for Managing the Care of Patients Receiving Oral Bisphosphonate Therapy: An Advisory Statement From the American Dental Association Council on Scientific Affairs. <i>J Am Dent Assoc.</i> 2008;139(12):1674-1677.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/19047674/pubmed" id="19047674" target="_blank">19047674</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Etidronate disodium tablets [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals, Inc; March 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20508948">
<a name="20508948"></a>Filleul O, Crompot E, and Saussez S. Bisphosphonate-Induced Osteonecrosis of the Jaw: A Review of 2,400 Patient Cases. <i>J Cancer Res Clin Oncol.</i> 2010;136(8):1117-1124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/20508948/pubmed" id="20508948" target="_blank">20508948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14594094">
<a name="14594094"></a>French AE, Kaplan N, Lishner M, et al. Taking Bisphosphonates During Pregnancy. <i>Can Fam Physician.</i> 2003;49:1281-1282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/14594094/pubmed" id="14594094" target="_blank">14594094</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gray RE. Severe Reaction to Diphosphonate. <i>BMJ.</i> 1988;297(6655):1042.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25404594">
<a name="25404594"></a>Green SB, Pappas AL. Effects of maternal bisphosphonate use on fetal and neonatal outcomes. <i>Am J Health Syst Pharm</i>. 2014;71(23):2029-2036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/25404594/pubmed" id="25404594" target="_blank">25404594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22041409">
<a name="22041409"></a>Hellstein JW, Adler RA, Edwards B, et al. Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Executive Summary of Recommendations From the American Dental Association Council on Scientific Affairs. <i>J Am Dent Assoc.</i> 2011;142(11):1243-1251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/22041409/pubmed" id="22041409" target="_blank">22041409</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Hellstein JW, Adler RA, Edwards B, et al. Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Recommendations From the American Dental Association Council on Scientific Affairs. 2011. http://www.ada.org/sections/professionalResources/pdfs/topics_ARONJ_report.pdf. Accessed February 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1580774">
<a name="1580774"></a>Hurvitz EA, Mandac BR, Davidoff G, Johnson JH, Nelson VS. Risk factors for heterotopic ossification in children and adolescents with severe traumatic brain injury. <i>Arch Phys Med Rehabil</i>. 1992;73(5):459-462.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/1580774/pubmed" id="1580774" target="_blank">1580774</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  IOM (Institute of Medicine). <i>Dietary Reference Intakes for Calcium and Vitamin D.</i> Washington, DC: The National Academies Press; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25414052">
<a name="25414052"></a>Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>J Bone Miner Res.</i> 2015;30(1):3-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/25414052/pubmed" id="25414052" target="_blank">25414052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19059370">
<a name="19059370"></a>Levy S, Fayez I, Taguchi N, et al. Pregnancy Outcome Following <i>in utero</i> Exposure to Bisphosphonates. <i>Bone.</i> 2009;44(3):428-430.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/19059370/pubmed" id="19059370" target="_blank">19059370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19772941">
<a name="19772941"></a>Lo JC, O'Ryan FS, Gordon NP, et al. Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure. <i>J Oral Maxillofac Surg.</i> 2010;68(2):243-253.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/19772941/pubmed" id="19772941" target="_blank">19772941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31539355">
<a name="31539355"></a>Machairiotis N, Ntali G, Kouroutou P, Michala L. Clinical evidence of the effect of bisphosphonates on pregnancy and the infant. <i>Horm Mol Biol Clin Investig</i>. 2019;40(2). doi:10.1515/hmbci-2019-0021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/31539355/pubmed" id="31539355" target="_blank">31539355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16243172">
<a name="16243172"></a>Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment. <i>J Oral Maxillofac Surg.</i> 2005;63(11):1567-1575.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/16243172/pubmed" id="16243172" target="_blank">16243172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17307586">
<a name="17307586"></a>Mavrokokki T, Cheng A, Stein B, et al. Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia. <i>J Oral Maxillofac Surg.</i> 2007;65(3):415-423.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/17307586/pubmed" id="17307586" target="_blank">17307586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3098781">
<a name="3098781"></a>Mital MA, Garber JE, and Stinson JT. Ectopic Bone Formation in Children and Adolescents With Head Injuries: Its Management. <i>J Pediatr Orthop.</i> 1987;7(1):83-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/3098781/pubmed" id="3098781" target="_blank">3098781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22885424">
<a name="22885424"></a>Pereira RM, Carvalho JF, Paula AP, et al. Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. <i>Rev Bras Reumatol.</i> 2012;52(4):580-593.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/22885424/pubmed" id="22885424" target="_blank">22885424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30803025">
<a name="30803025"></a>Ralston SH, Corral-Gudino L, Cooper C, et al. Diagnosis and management of Paget's disease of bone in adults: a clinical guideline<i>. J Bone Miner Res</i>. 2019;34(4):579-604. doi: 10.1002/jbmr.3657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/30803025/pubmed" id="30803025" target="_blank">30803025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25234529">
<a name="25234529"></a>Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <i>J Oral Maxillofac Surg</i>. 2014;72(10):1938-1956. doi: 10.1016/j.joms.2014.04.031.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/25234529/pubmed" id="25234529" target="_blank">25234529</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ruggiero S, Gralow J, Marx RE, et al. Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer. <i>J Clin Oncol.</i> 2006;2(1):7-14.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8291954">
<a name="8291954"></a>Silverman SL, Hurvitz EA, Nelson VS, et al. Rachitic Syndrome After Disodium Etidronate Therapy in an Adolescent. <i>Arch Phys Med Rehabil. </i>1994;75(1):118-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/8291954/pubmed" id="8291954" target="_blank">8291954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25406796">
<a name="25406796"></a>Singer FR, Bone HG, Hosking DJ, et al. Paget's disease of bone: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2014;99(12):4408-4422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/25406796/pubmed" id="25406796" target="_blank">25406796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30171300">
<a name="30171300"></a>Sokal A, Elefant E, Leturcq T, Beghin D, Mariette X, Seror R. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. <i>Osteoporos Int</i>. 2019;30(1):221-229.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/30171300/pubmed" id="30171300" target="_blank">30171300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22281884">
<a name="22281884"></a>Stathopoulos IP, Liakou CG, Katsalira A, et al. The Use of Bisphosphonates in Women Prior to or During Pregnancy and Lactation. <i>Hormones (Athens).</i> 2011;10(4):280-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/22281884/pubmed" id="22281884" target="_blank">22281884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2109197">
<a name="2109197"></a>Storm T, Thamsborg G, Steiniche T, et al. Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women With Postmenopausal Osteoporosis. <i>N Engl J Med.</i> 1990;322(18):1265-1271.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/2109197/pubmed" id="2109197" target="_blank">2109197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21327429">
<a name="21327429"></a>Vujasinovic-Stupar N, Pejnovic N, Markovic L, Zlatanovic M. Pregnancy-associated spinal osteoporosis treated with bisphosphonates: long-term follow-up of maternal and infants outcome. <i>Rheumatol Int</i>. 2012;32(3):819-823.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/21327429/pubmed" id="21327429" target="_blank">21327429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2113611">
<a name="2113611"></a>Watts NB, Harris ST, Genant HK, et al. Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis. <i>N Engl J Med.</i> 1990;323(2):73-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/2113611/pubmed" id="2113611" target="_blank">2113611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16899779">
<a name="16899779"></a>Whyte MP. Clinical Practice. Paget's Disease of Bone. <i>N Engl J Med.</i> 2006;355(6):593-600.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/16899779/pubmed" id="16899779" target="_blank">16899779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19118315">
<a name="19118315"></a>Wysowski DK. Reports of Esophageal Cancer With Oral Bisphosphonate Use. <i>N Engl J Med.</i> 2009;360(1):89-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etidronate-united-states-not-available-pediatric-drug-information/abstract-text/19118315/pubmed" id="19118315" target="_blank">19118315</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13291 Version 161.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
